← back to search

Dinesh Saralaya

Bradford Teaching Hospitals NHS Foundation Trust · GB
Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Asthma and respiratory diseases, Inhalation and Respiratory Drug Delivery, Chronic Obstructive Pulmonary Disease (COPD) Research, and SARS-CoV-2 and COVID-19 Research.
h-index
27
citations
4,664
works
103
NIH funding
primary concept
Medicine
email

Recent publications

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
The Lancet Respiratory Medicine 2024cited by 59position: middledoi
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study
American Journal of Respiratory and Critical Care Medicine 2024cited by 24position: middledoi
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
The Lancet Infectious Diseases 2023cited by 53position: middledoi
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Clinical Infectious Diseases 2022cited by 73position: middledoi
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
2021cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ashwani Kumar Arora · Novartis (Switzerland)1 papers (2021–2021)Luís Puente‐Maestu · Universidad Complutense de Madrid1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021)Luca Moraschini · Novartis (Switzerland)1 papers (2021–2021) · 1 papers (2021–2021)Guy Brusselle · University of Colorado Denver1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021)Edward Kerwin · Novartis (Switzerland)1 papers (2021–2021)Wim Janssens · KU Leuven1 papers (2021–2021)Alberto Papi · Instituto de Investigación Sanitaria de Santiago1 papers (2021–2021) · 1 papers (2021–2021)Maria Lattanzi · Novartis (Switzerland)1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021)Tom Wilkinson · Southampton General Hospital1 papers (2021–2021)